Clinical Trial Update: Niraparib and Dostarlimab in HRD Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update involving niraparib and dostarlimab in homologous recombination deficiency solid tumors (HRD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homologous Recombination Deficiency Solid Tumors

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: West Cancer Center | Conditions: Homologous Recombination Deficient Solid Tumors | Phase 2 | Status: UNKNOWN